Dr Rita Ferreira
Areas of expertise
- Cell Development, Proliferation And Death 310102
- Genome Structure And Regulation 310508
- Epigenetics (Incl. Genome Methylation And Epigenomics) 310504
- Cancer Cell Biology 321101
Biography
2016-2018 : Senior Scientist, Horizon Discovery, Cambridge, UK
2011-2016 : Senior Scientist, Neusentis, Pfizer, Cambridge, UK
2005-2011 : Research Associate (Postdoctoral Fellow), Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
2004-2005 : Postdoctoral Fellow, Erasmus Medical Centre, Rotterdam, The Netherlands
1999-2004 : PhD in Cell Biology, Erasmus University, Rotterdam, The Netherlands
Publications
- Amarasiri, M, VO, Y, Gardiner, M et al. 2021, 'The Synthesis and Biological Evaluation of Some C-9 and C-10 Substituted Derivatives of the RNA Polymerase I Transcription Inhibitor CX-5461', Australian Journal of Chemistry, vol. 74, no. 7, pp. 540-556.
- Ferreira, R, Schneekloth Jr., J, Panov, K et al. 2020, 'Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age', Cells, vol. 9, no. 2.
- Franks, S, Firipis, K, Ferreira, R et al. 2020, 'Harnessing the self-assembly of peptides for the targeted delivery of anti-cancer agents', Materials Horizons, vol. 7, no. 8, pp. 1996-2010.
- Schwartzentruber, J, Foskolou, S, Kilpinen, H et al. 2018, 'Molecular and functional variation in iPSC-derived sensory neurons', Nature Genetics, vol. 50, no. 1, pp. 54-61.
- Skerratt, S, Humphreys, S, Ferreira, R et al. 2016, 'Identification of a novel BODIPY minihepcidin tool for the high content analysis of ferroportin (SLC40A1) pharmacology', RSC Medicinal Chemistry (Formerly MedChemComm), vol. 7, no. 8, pp. 1564-1571.
Projects and Grants
Grants information is drawn from ARIES. To add or update Projects or Grants information please contact your College Research Office.
- Advancing health equity for Indigenous Australians through pharmacogenomics: building an end-to-end discovery pipeline (Secondary Investigator)
- Molecular pathways that control platelet production (Secondary Investigator)
- Evaluating the potential of combinatorial therapy with RNA polymerase I inhibitors to counteract chemotherapy-induced thrombocytopenia (Primary Investigator)
